Home / Health / NICE Approves New Lung Cancer Drug for NHS
NICE Approves New Lung Cancer Drug for NHS
22 Jan
Summary
- NICE now recommends Amivantamab with lazertinib for specific lung cancer patients.
- Previously, NICE considered not funding the drug in the NHS in England.
- The drug must be funded in England within 90 days of final guidance publication.
In a significant development for lung cancer treatment, the National Institute for Health and Care Excellence (NICE) has published its final guidance. This recommendation greenlights the use of Amivantamab in combination with lazertinib for individuals diagnosed with untreated EGFR mutation-positive advanced non-small-cell lung cancer.
This decision marks a reversal from NICE's initial consultation stage in July 2025. At that time, draft guidance indicated that Amivantamab plus lazertinib might not be routinely funded by the NHS in England. However, following further review, NICE has determined that sufficient evidence supports the drug's benefits and value for money.
The final guidance mandates that Amivantamab plus lazertinib must be funded by the NHS in England for the specified patient group. This funding is required to be in place within 90 days of the guidance's final publication, ensuring timely access to this advanced treatment option for eligible patients.
